A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II. (1st October 2022)

• Record Type: Journal Article
• Authors: Knöchel, Jane; Nilsson, Catarina; Carlsson, Björn; Wernevik, Linda; Hofherr, Alexis; Gennemark, Peter; Jansson‐Löfmark, Rasmus; Isaksson, Rikard; Rydén‐Bergsten, Tina; Hamrén, Bengt; Rekić, Dinko
• Is Part Of: CPT: pharmacometrics & systems pharmacology. Volume 11:Number 12(2022)
• Page Start: 1569
• Page End: 1577
• Publication Date: 2022-10-01
• Subjects: Pharmacokinetics -- Periodicals; Pharmacology -- Periodicals; Pharmacokinetics; Periodicals; 615.05
• DOI: 10.1002/psp4.12866
• Languages: English
• ISSNs: 2163-8306

Abstract

Abstract: Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐human study, utility of the US Food and Drug Administration MIDD pilot program to accelerate timelines, innovative use of competitor data to set biomarker targets, and use of MIDD to optimize sample size and dose selection, as well as to accelerate and de‐risk a phase IIb study. The focus of the case‐study is on the cross‐functional collaboration and other key MIDD enablers that are critical to maximize the value of MIDD, rather than the technical application of MIDD.